Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results.

Authors

Carsten Nieder, Luka Stanisavljevic, Ellinor C Haukland, Bård Mannsåker, Bence Fajth, Astrid Dalhaug

Published in

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. Jun 25, 2026. Epub Jun 25, 2026.

Abstract

This article describes a regional study performed in patients with bone metastases from prostate cancer hypothesizing that intensified radiotherapy (metastases directed and prostate directed) may result in longer overall survival.
A retrospective study of 246 consecutive male patients who received 347 courses of radiotherapy in the time period 2011-2025 was performed. Patients were stratified into three cohorts spanning 5‑year intervals (2011-2015, 2016-2020, 2021-2025). Survival was analyzed in allcomers and separately in patients without visceral metastases treated within the first year after diagnosis (n = 119).
Median overall survival was shortest in the earliest phase of the study (2011-15). The two recent cohorts had similar survival. Outpatients with high performance status irradiated early after diagnosis and to all known sites of disease experienced superior survival. In the subgroup of 119 patients, simultaneous prostate radiotherapy prolonged survival (numerically better than no prostate RT, median 40 vs. 26 months, 5‑year rate 47 vs. 18%, p = 0.11). The impact of bone radiotherapy dose (dichotomized < 3 Gy × 13 or its biological equivalent vs. higher doses) was significant (if synchronous metastases, 5‑year rate 64 vs. 17%, p = 0.026; if metachronous metastases, 5‑year rate 48 vs. 8%, p < 0.001). Bone dose remained significant in multivariate analyses, together with clinical baseline parameters.
In our healthcare region, outcomes largely resemble those of prospective trials. Comprehensive radiotherapy to the prostate and bone oligometastases plus guideline-based systemic therapy resulted in favorable 5‑year survival.

PMID:
42347870
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.